Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial
2013; Elsevier BV; Volume: 15; Issue: 2 Linguagem: Inglês
10.1016/s1470-2045(13)70554-0
ISSN1474-5488
AutoresHelena Earl, Anne-Laure Vallier, Louise Hiller, Nicola Fenwick, Jennie Young, Mahesh Iddawela, Jean Abraham, Luke Hughes‐Davies, Ioannis Gounaris, Karen McAdam, Stephen Houston, Tamas Hickish, Anthony Skene, Stephen Chan, Susan Dean, Diana Ritchie, Robert Laing, Mark Harries, Christopher M. Gallagher, Gordon Wishart, Janet Dunn, Elena Provenzano, Carlos Caldas,
Tópico(s)HER2/EGFR in Cancer Research
ResumoAnthracyclines and taxanes have been the standard neoadjuvant chemotherapies for breast cancer in the past decade. We aimed to assess safety and efficacy of the addition of gemcitabine to accelerated paclitaxel with epirubicin and cyclophosphamide, and also the effect of sequencing the blocks of epirubicin and cyclophosphamide and paclitaxel (with or without gemcitabine).
Referência(s)